US court limits mail-order access to abortion pill mifepristone

May 2, 2026

The Fifth Circuit Court of Appeals has issued a ruling that temporarily blocks the mailing of mifepristone abortion pills, requiring patients to obtain them in person instead. This decision reinstates previous restrictions by pausing a 2023 FDA regulation that had permanently allowed telemedicine prescribing and mail delivery of the medication, which had been expanded during the COVID-19 pandemic. The ruling stems from a Louisiana lawsuit and will remain active while legal proceedings continue, particularly affecting access in states with abortion bans despite mifepristone being widely available where abortion remains legal.

Who is affected

Women seeking abortion services, particularly those in states where abortion is banned
Doctors who prescribe mifepristone through telemedicine
Louisiana residents subject to the state's abortion ban
Over 3.7 million women who have used mifepristone in the US between 2000-2018
Women who use mifepristone for miscarriage treatment and Cushing syndrome
The FDA (Food and Drug Administration)

What action is being taken

The Fifth Circuit Court of Appeals is restricting access to mifepristone by mail
An in-person dispensing requirement for abortion pills is being reinstated
The Trump administration is conducting an FDA review
New York is continuing to protect abortion access, including medication abortion, under state law

Why it matters

This ruling significantly impacts abortion access in the United States, particularly affecting the most common method of pregnancy termination. By requiring in-person dispensing, the decision creates substantial barriers for women in states with abortion bans who previously could access the medication through telemedicine and mail delivery. The ruling undermines the FDA's medical and scientific determination that telemedicine prescribing is safe, with mainstream medical organizations supporting the safety and efficacy of the medication (95% effective with less than 1% requiring further medical follow-up).

What's next

The decision will remain in effect as the case continues to play out in the courts, and the Trump administration is conducting an FDA review of the regulations.

Read full article from source: BBC